Skip to main content

Dr. Reddy's Laboratories Ltd ADR(RDY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low13.40
Day High13.67
Open:13.56
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Dr. Reddy's Laboratories Ltd ADR

Select a category then submit the form to load news
Tipranks
Dr. Reddy’s Schedules May 12 Board Meeting to Approve FY 2026 Results, Closes Trading Window
Tipranks
Dr. Reddy’s Launches India’s First DCGI-Approved Generic Semaglutide Obeda for Type 2 Diabetes
Tipranks
Dr. Reddy’s Faces GST Penalty Orders for FY 2019–22, Sees No Material Impact
Tipranks
Dr. Reddy’s Flags Phase III Setback as Immutep Halts Key Lung Cancer Trial
Tipranks
Dr. Reddy’s Allots New ESOP Shares, Slightly Increases Equity Capital
Tipranks
Dr. Reddy’s Cleared by Delhi High Court to Export Semaglutide to Non-Patent Markets
Tipranks
Dr. Reddy’s Cleared as U.S. DOJ Closes FCPA Inquiry Without Enforcement
Zacks Investment Research
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's
Zacks Investment Research
3 Generic Drug Stocks to Watch Despite Industry Headwinds
3 Generic Drug Stocks to Watch Despite Industry Headwinds
Tipranks
Dr. Reddy’s Schedules Analyst and Investor Meets for Early March 2026
Tipranks
Geojit Research Keeps Their Hold Rating on Dr. Reddy’s Laboratories Ltd. (DRREDDY)
Tipranks
Dr. Reddy’s Says SEC Ends FCPA Probe Without Recommending Enforcement Action
Tipranks
Dr. Reddy’s Buys Progynova HRT Brands in India to Bolster Gynecology Portfolio
Tipranks
Dr. Reddy’s Allots 12,665 ESOP Shares, Nudging Up Equity Capital
Tipranks
Dr. Reddy’s Schedules Mumbai Investor Meet for February 23, 2026
Tipranks
Dr. Reddy’s Announces May Exit of Global Head of IPDO Sushrut Kulkarni
Tipranks
Dr. Reddy’s Schedules Nuvama Investor Conference Meetings in Mumbai on February 9, 2026
Tipranks
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement
Tipranks
Dr. Reddy’s Q3 Earnings Call: Growth Amid Margin Strain
Tipranks
Dr. Reddy’s Russian Subsidiary Faces VAT Reclassification Penalty Deemed Immaterial
Tipranks
Dr. Reddy’s Launches First-to-Market Generic of Extra-Strength Pataday in U.S. OTC Eye-Care Segment
Tipranks
Dr. Reddy’s Receives USFDA Post-Application Action Letter for Bachupally Biologics Facility
Tipranks
Dr. Reddy’s to Announce Q3 FY26 Results and Host Earnings Call on January 21, 2026
Tipranks
Dr. Reddy’s Faces GST Penalty Orders for FY 2018–23, Sees No Material Financial Impact
Tipranks
Dr. Reddy’s Faces FDA Setback on AVT03 Denosumab Biosimilar After Manufacturing Inspection
Tipranks
Dr. Reddy’s Schedules January 21 Board Meeting to Review Q3 FY26 Results, Closes Trading Window
Tipranks
Dr. Reddy’s Laboratories to Engage with Investors at Chennai Conference
Tipranks
Dr. Reddy’s Laboratories Receives USFDA Observations Post-Inspection
Tipranks
Bank of America Securities Keeps Their Buy Rating on Dr. Reddy’s Laboratories Ltd. (DRREDDY)
Tipranks
Dr. Reddy’s Laboratories Allots Equity Shares Under ESOPs
Tipranks
Dr. Reddy’s and Immutep Forge Strategic Partnership for Eftilagimod Alfa
Zacks Investment Research
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's

Profile

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.